Can you point me in the direction of the announcements by LGP and AGH? I have only seen announcements by CAN and they haven't looked all that positive based on the termination of their originally announced partnership with Emyria.
As far as I can tell, they are currently designing their phase 3 trial (whereas it looks like we are currently doing a Phase 2b trial). Can someone explain the difference and provide rough timing estimations? It looks like CAN has announced that they are aiming for approval by the end of CY2022 and they seem to be ahead of the pack in this respect (with us next in line from what I can gauge).
Cannatrek, which I believe signed a partnership with Chemist Warehouse, looks like it has not even started trials... can someone confirm?
Can you point me in the direction of the announcements by LGP...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| BOD (ASX) Chart |
Day chart unavailable